Retatrutide vs Semaglutide: What the Phase 3 Trials Show
Last updated: · Phase 3 TRIUMPH-1 results →
Semaglutide 2.4 mg (Wegovy) produced a −14.9% mean change in body weight at 68 weeks in STEP 1. Tirzepatide 15 mg produced −20.9% at 72 weeks in SURMOUNT-1. Retatrutide's Phase 3 TRIUMPH-1 trial, published in the New England Journal of Medicine in September 2026, reported −25.0% at 12 mg over 80 weeks, vs −3.9% with placebo; Phase 2 had reported 24.2% at 48 weeks (Jastreboff et al., NEJM 2023). These are cross-trial comparisons, not a single head-to-head RCT. Here's what makes the triple agonist different and what the data shows.
(Retatrutide TRIUMPH-1, 12mg/80wk)
(STEP-1, 68wk)
(vs 1 for Ozempic)
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar — your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
Average Weight Loss: Cross-Trial Comparison
All three drugs compared. Percentages represent average body weight reduction across clinical trial populations. Cross-trial comparisons have limitations — different patient populations and trial designs.
Cross-trial caveat: These drugs were tested in separate clinical trials with different patient populations. Direct head-to-head comparison does not exist yet. The data reflects each drug's average reported weight loss in its respective trials. Individual results vary significantly based on starting weight, diet, exercise, and adherence.
Evidence status. Retatrutide's figure is the published TRIUMPH-1 primary analysis (N Engl J Med, September 29, 2026; PMID 42814954): −25.0% at 12 mg over 80 weeks, using the treatment-regimen (intention-to-treat) estimand. Eli Lilly's May 2026 topline release reported a larger figure using the efficacy estimand, which assumes everyone stayed on treatment; the semaglutide (−14.9%) and tirzepatide (−20.9%) figures here are the treatment-regimen results from STEP 1 (PMID 33567185) and SURMOUNT-1 (PMID 35658024), so all three use the same kind of estimate. Every figure on this page is a cross-trial comparison (retatrutide vs placebo in TRIUMPH-1; semaglutide STEP 1; tirzepatide SURMOUNT-1) — not a single head-to-head RCT.
The Triple Receptor Advantage
Semaglutide hits one target. Tirzepatide hits two. Retatrutide hits three — and the third target (glucagon) is the main mechanistic difference.
GLP-1 + GIP + Glucagon receptor activation simultaneously. Semaglutide activates only GLP-1 (appetite/satiety). Tirzepatide adds GIP (insulin sensitivity, fat storage). Retatrutide adds glucagon receptor activity, which is proposed to raise energy expenditure; the cited retatrutide trials did not measure this directly.
Glucagon receptor activation is hypothesized to add energy expenditure and fat oxidation on top of reduced food intake. Most GLP-1 drugs work primarily by reducing food intake; whether retatrutide's glucagon component raises energy expenditure in humans is not yet established.
Like other GLP-1-based drugs, retatrutide acts on central appetite circuits to reduce food intake. Descriptions of reduced "food noise" are anecdotal and have not been measured as an outcome in its published trials.
In phase 2 studies retatrutide reduced liver fat (PMID 38858523) and, in people with type 2 diabetes, lowered HbA1c (PMID 37385280). Whether these effects go beyond what weight loss alone explains has not been established.
What It Actually Costs
Pricing varies by channel, insurance, and manufacturer programs, and changes often. Check current prices with a pharmacy or prescriber.
⚠️ Research peptide vendors: Not FDA-regulated, not intended for human therapeutic use, quality varies significantly by vendor. Retail brand drugs are FDA-approved and physician-supervised. Know the difference and the risks of each option.
Phase 3 Timeline
Where retatrutide stands in its path to FDA approval as of October 2026 — after the TRIUMPH-1 publication. Full Phase 3 breakdown →
🦴 Semaglutide's Cartilage Finding: Does Retatrutide Do The Same?
A 2026 Cell Metabolism study (Qin et al.) demonstrated a weight loss-independent mechanism for semaglutide's effect on joint cartilage. In an obese mouse model of osteoarthritis, semaglutide reduced cartilage degeneration, osteophyte formation, synovial lesion and pain sensitivity. Using a diet-controlled design that ruled out appetite suppression and weight loss, the authors showed semaglutide regulates the GLP-1R-AMPK-PFKFB3 axis, reprogramming chondrocyte metabolism from glycolysis to oxidative phosphorylation under inflammatory conditions — resulting in cartilage restoration. A randomized pilot clinical study (ChiCTR2200066291) further supports these findings.
Read that carefully: the mechanism is demonstrated mostly in mice. The human evidence is a small randomized pilot study (ChiCTR2200066291). Treat it as a preliminary signal, not an established effect, pending larger trials.
Citation: Qin H, et al. (2026). "Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism." Cell Metabolism 38(3):582-597.e6. PMID 41666927 · DOI: 10.1016/j.cmet.2026.01.008
Whether retatrutide — a triple agonist (GLP-1/GIP/glucagon) — produces similar cartilage regeneration is not yet established in published literature. GLP-1 receptor activation appears to be the key driver; retatrutide does target GLP-1R, so the mechanism could theoretically apply, but no retatrutide study has measured cartilage structure. TRIUMPH-1 did report reduced knee-osteoarthritis pain in its 574-participant subgroup (WOMAC pain change −3.6 at 12 mg vs −1.9 with placebo; PMID 42814954).
→ Full Research Breakdown: Semaglutide and Cartilage Regeneration
Mental Clarity, Cognition & Inflammation
Beyond fat loss: the receptor-level rationale for effects on cognition and inflammation — and where the evidence stops.
Cognition. GLP-1 receptors are expressed in the hippocampus and prefrontal cortex — the regions behind memory and executive focus. In randomized trials, in a phase 2b mild-to-moderate Alzheimer's trial of liraglutide, one secondary executive-function score favoured liraglutide (unadjusted) while daily-function and dementia-rating scores did not differ, and the trial did not meet its primary endpoint (cerebral glucose metabolism) (Edison et al. 2026, PMID 41326666) — and exenatide preserved off-medication motor function in a phase 2 Parkinson's trial (Athauda et al. 2017, PMID 28781108), but the larger phase 3 Exenatide-PD3 trial found no difference from placebo at 96 weeks (Lancet 2025, PMID 39919773). Retatrutide adds GIP receptor activity, which has neurotrophic effects in preclinical models; whether that translates into cognitive effects in people is untested.
Inflammation. GLP-1 / GIP dual agonism reduced neuroinflammation and protected synaptic numbers and synaptic activity across multiple preclinical Alzheimer's and Parkinson's models (Hölscher review, PMID 29402504). Systemically, much of the anti-inflammatory benefit is downstream of fat loss itself: visceral adipose tissue is a primary source of IL-6 and TNF-α, and retatrutide produces large body-weight reductions — 24.2% mean body weight loss at 48 weeks (12 mg) in the Phase 2 obesity trial (Jastreboff et al. 2023, PMID 37366315). Less adipose mass means less inflammatory signaling.
Key Takeaways
- −25.0% mean body weight change at 80 weeks (12 mg) in Phase 3 TRIUMPH-1 (NEJM 2026), vs −14.9% for semaglutide (STEP 1, 68 weeks) and −20.9% for tirzepatide 15 mg (SURMOUNT-1, 72 weeks) — separate trials, not head-to-head; Phase 2 reported 24.2% at 48 weeks (NEJM 2023)
- Retatrutide adds GIP and glucagon receptor activity to GLP-1 agonism; how much each receptor contributes in humans is not established
- Retatrutide adds glucagon receptor activity that semaglutide lacks; its effect on energy expenditure in humans is not established by the cited trials
- Phase 2 data published and publicly available
- Phase 3 TRIUMPH-1 is published (NEJM 2026); the broader TRIUMPH program (including cardiovascular outcomes) continues
- In Phase 2, GI events were the most common adverse events; they were dose-related and mostly mild to moderate, and heart rate rose in a dose-dependent manner
- Safety beyond the 80-week Phase 3 period, and the eventual FDA label, are not yet established
- Cardiovascular outcome data still pending
- Not FDA approved as of October 2026
- Long-term weight maintenance after discontinuation not fully characterized
- Research peptide quality is unregulated — purity and identity not guaranteed
- No head-to-head RCT directly comparing retatrutide vs tirzepatide
🛒 Recommended Supplies
Research supplies relevant to injectable GLP-1 class peptides.
Affiliate links — support HighPeptides at no extra cost.
Related Resources
Swiss Chems
HighPeptides earns a commission on purchases. Lab-test standing and regulatory notices for every vendor we track, including this one, are on our vendors page.
Browse Swiss Chems →Affiliate links — support HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide — $19 (normally $29) →
New to peptides? Start with the $19 Buyer’s Playbook →
This page is for educational and informational purposes only. It is not medical advice. Retatrutide (LY3437943) is NOT currently FDA-approved for human use. It is an investigational compound; Phase 3 TRIUMPH-1 was published in the New England Journal of Medicine in September 2026, and retatrutide is not FDA-approved as of October 2026. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are FDA-approved but require a prescription. Weight loss percentages cited reflect clinical trial averages — individual results vary. Research peptide vendors are not FDA-regulated; purity and identity are not guaranteed. Always consult a qualified healthcare provider before use. HighPeptides does not sell peptides or endorse their use outside of legitimate research settings.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.